Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 13, 2023 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
October 10, 2023 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®

BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
September 22, 2023 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Presents New Data at ESPE 2023

BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
September 19, 2023 08:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
September 08, 2023 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
September 08, 2023 07:59 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Update to September Conference Participation

BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
September 06, 2023 07:59 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
August 28, 2023 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present at Investor Conferences in September

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
August 07, 2023 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

-- Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment ---- Early access designation for hypothalamic obesity comes in addition...
August 04, 2023 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...